OncoGenex Pharmaceuticals, Inc. (OGXI)

Oncology Corporate Profile

Stock Performance

0.4700
0.0000

HQ Location

1522 217th Place SE, Suite 100
Bothell, WA 98021

Company Description

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

Website: http://www.oncogenex.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
custirsen / OGX-011/TV-1011clusterin inhibitor1st line metastatic castrate-resistant Prostate cancer (CRPC)IIITeva
custirsen / OGX-011/TV-1011clusterin inhibitor1st line metastatic Non Small Cell Lung Cancer (NSCLC)IIITeva
custirsen (+ cabazitaxel) / OGX-011/TV-1011clusterin inhibitor2nd line metastatic castrate-resistant prostate cancer (CRPC)IIITeva
apatorsen (+ abiraterone acetate) / OGX-427Hsp27 inhibitor1st line metastatic Prostate cancerII
apatorsen / OGX-427Hsp27 inhibitorBladder cancerII
apatorsen (+ docetaxel) / OGX-427Hsp27 inhibitorBladder cancerII
apatorsen / OGX-427 (+ carboplatin and pemetrexed)Hsp27 inhibitorNon Small Cell Lung Cancer (NSCLC)II
apatorsen / OGX-427Hsp27 inhibitorNon Small Cell Lung Cancer (NSCLC)II
apatorsen / OGX-427Hsp27 inhibitorPancreatic cancerII
OGX-225IGFBP-2, -5 inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source


http://www.oncogenex.com

Recent News Headlines

OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial in Metastatic Bladder Cancer

10/26/2016 11:41 am

(OncoGenex) Oct 25, 2016 - OncoGenex Pharmaceuticals, Inc. announced today positive survival results from the final analysis of the Phase 2 Borealis-2™ trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy.

OncoGenex Announces Results From the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer

10/13/2016 06:45 am

(OncoGenex) Oct 13, 2016 - OncoGenex Pharmaceuticals, Inc. announced today results from the final analysis of the Phase 3 ENSPIRIT trial of custirsen in patients whose non-small cell lung cancer (NSCLC) has progressed following initial treatments.

OncoGenex Seeks Strategic Alternatives After Drug Study Fails

8/16/2016 10:48 am

(Reuters) Aug 16, 2016 - OncoGenex Pharmaceuticals Inc said it was exploring strategic alternatives after its experimental drug failed to show survival benefit in a late-stage study in patients with advanced prostate cancer.

OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

8/16/2016 06:47 am

(OncoGenex) Aug 16, 2016 - OncoGenex Pharmaceuticals, Inc. announced today results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with docetaxel.

Inherited Mutation Doubles The Risk Of Death From Malignant Melanoma

6/15/2016 11:05 am

(Karolinska Institutet [Stockholm, Sweden]) June 13, 2016 - People with malignant melanoma with an inherited mutation in a certain gene are twice as likely to die of the disease, according to a new study.

Kaiser Permanente Study Finds Breast Cancer Patients Taking Newer Hormone Therapy Drugs Have No Increased Risk of Fatal Cardiovascular Events

4/22/2016 11:01 am

(Kaiser Permanente) Apr 21, 2016 - In a new study, researchers found the use of aromatase inhibitors was not associated with an increased risk of fatal cardiovascular events compared with tamoxifen.

Young Adult Survivors Of Childhood Cancer Report Overall Health Similar To Middle-Aged In General Population

4/22/2016 11:01 am

(Harvard T.H. Chan School of Public Health) Apr 21 2016 - According to new research from Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard T.H. Chan School of Public Health, overall health-related quality of life in young adult survivors of childhood cancer resembles that of middle-aged adults.

OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities

2/5/2016 12:31 pm

(Yahoo! Finance) Feb 4, 2016 - OncoGenex Pharmaceuticals, Inc. announced today that it is implementing a plan to reduce operating expenses, including a workforce reduction of approximately 27%.

Minority of Cancer Cells Affect The Growth And Metastasis Of Tumors

2/3/2016 11:04 am

(Lund University [Sweden]) Feb 2, 2016 - New research shows that a small minority of cancer cells in neuroendocrine tumours of the pancreas contribute to the overall growth and metastasis of the tumour. This discovery was made by a research group at Lund University, in collaboration with researchers at Karolinska Institutet, in Sweden.

OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer

1/21/2016 11:49 am

(StreetInsider) Jan 20, 2016 - OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce™ trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis

12/9/2015 01:47 pm

(Morningstar) Dec 9, 2015 - OncoGenex Pharmaceuticals, Inc. announced today that the independent Data Safety Monitoring Board (DSMB) at Dana-Farber/Harvard Cancer Center has recommended that the Phase 2 Borealis-2™ trial continue as planned after completing the pre-specified futility analysis.

OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses

12/2/2015 11:57 am

(MarketWatch) Dec 1, 2015 - Final results expected in second half of 2016.

OncoGenex Announces EMA Support for Phase 3 AFFINITY Trial Protocol Amendment

10/9/2015 11:51 am

(OncoGenex) Oct 8, 2015 - Topline results in poor prognosis subpopulation expected by end of year.

OncoGenex Announces Completion of Patient Enrollment in Borealis-2™ Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer

9/30/2015 11:38 am

(Morningstar) Sept 30, 2015 - OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2™, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients.

OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Survival in Those at Increased Risk for Poor Outcomes

9/28/2015 01:57 pm

(Morningstar) Sept 28, 2015 - OncoGenex Pharmaceuticals, Inc. announced today results from additional exploratory analyses of the Phase 3 SYNERGY trial demonstrating that custirsen treatment significantly lowered serum clusterin (sCLU) levels from baseline in men with metastatic castrate-resistant prostate cancer (mCRPC).

OncoGenex's Pancreatic Cancer Drug Found Ineffective In Study

9/23/2015 11:32 am

(Reuters) Sept 23, 2015 - Drug developer OncoGenex Pharmaceuticals Inc said its experimental combination therapy for pancreatic cancer was not effective in a mid-stage study.

OncoGenex Announces Phase 2 Rainier Results in Previously Untreated Metastatic Pancreatic Cancer

9/23/2015 07:00 am

(MarketWatch) Sept 23, 2015 - The addition of apatorsen to ABRAXANE and gemcitabine did not demonstrate a survival benefit compared to ABRAXANE and gemcitabine alone.

Mallinckrodt Buys Immunotherapy Maker Therakos For $1.33 Billion

8/10/2015 11:05 am

(Reuters) Aug 10, 2015 - Dublin-based drugmaker Mallinckrodt Plc said it would buy immunotherapy company Therakos Inc in a deal valued at about $1.33 billion, its second major acquisition this year aimed at strengthening its hospital offerings.

Cancer Genetics of Rutherford Agrees To Buy Los Angeles-Based Company

8/10/2015 11:05 am

(NorthJersey.com/The Record) Aug 10, 2015 - Cancer Genetics Inc. said Monday it agreed to buy Los Angeles-based Response Genetics Inc. for $14 million, adding expertise in solid tumor molecular diagnosis.

OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis

7/13/2015 07:20 am

(OncoGenex) July 13, 2015 - OncoGenex Pharmaceuticals, Inc. announced today that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per the recommendation of an Independent Data Monitoring Committee (IDMC).

FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment

6/10/2015 11:56 am

(StreetInsider) June 10, 2015 - Co-primary survival endpoint included for a prospectively-defined poor prognosis subpopulation.

OncoGenex Announces Data From Borealis-1(TM) Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer

6/1/2015 06:19 pm

(MarketWatch) June 1, 2015 - OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1™ trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis

5/30/2015 06:30 pm

(Yahoo! Finance) May 30, 2015 - OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

Mediterranean Diet Reduces Risk of Womb Cancer, Study

5/27/2015 11:05 am

(French Tribune) May 27, 2015 - According to a new study, adapting a Mediterranean diet can significantly reduce to risk of getting womb cancer. The researchers found that those who followed a Mediterranean diet have lowered their risk of womb cancer by 57 per cent.

Clinical Trial Reduces Stress of Cancer Caregivers

5/27/2015 11:05 am

(UCCC/In the Clinic blog) May 26, 2015 - Cancer caregivers are stressed, potentially impacting the quality of the care they give. A CU Cancer Center clinical trial demonstrates how to help.

AstraZeneca-Novartis Three-Drug Melanoma Treatment Found Safe

5/14/2015 12:05 pm

(Bloomberg) May 13, 2015 - A first-of-its-kind combination of three drugs to treat a deadly form of skin cancer can be taken safely, passing the first hurdle to regulatory approval for a potentially long-lasting treatment.

OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update

4/30/2015 12:15 pm

(Yahoo! Finance) Apr 30, 2015 - OncoGenex Pharmaceuticals, Inc. announced today it has filed an amendment with the U.S. Food and Drug Administration, as well as initiated filing with regulatory agencies in other countries, to amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC).

OncoGenex Regains Rights to Custirsen from Teva

4/27/2015 11:20 am

(OncoGenex) Apr 27, 2015 - OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers.

FDA Kicks off Generic Drug User Fee Reauthorization Process

4/22/2015 12:00 pm

(RAPS/Regulatory Focus) Apr 21, 2015 - Regulators and generic pharmaceutical companies, start your engines. The race to the next reauthorization of the Generic Drug User Fee Act (GDUFA) has begun.

Genetic Test Could Help Identify Breast Cancer Risk

4/9/2015 11:04 am

(Cancer Research UK/Press Association) Apr 9, 2015 - UK researchers have taken a step towards identifying women at increased risk of breast cancer by analysing their DNA.

New Waldenström’s Drug Shows Sustained Benefit at Two Years

4/9/2015 11:04 am

(Dana-Farber) Apr 8, 2015 - The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenström’s Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute.

Biggest U.S. Health Insurer Tightens Rules on Hysterectomy Coverage

2/27/2015 11:05 am

(Wall Street Journal) Feb 26, 2015 - UnitedHealth to require doctors to get authorization before performing most types of procedures; decision marks another blow to laparoscopic power morcellator, which can spread hidden cancer.

OncoGenex and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce(TM) Clinical Trial Evaluating Apatorsen in Combination with Carboplatin and Pemetrexed in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

2/24/2015 12:10 pm

(NJ.com) Feb 24, 2015 - OncoGenex Pharmaceuticals, Inc. and Sarah Cannon announced today that patient enrollment has been completed in the Spruce™ clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with carboplatin and pemetrexed in patients with previously untreated, advanced, non-squamous, non-small cell lung cancer (NSCLC).

Allegheny Health Network Physician Research Points to Possible New Paradigm in Ovarian Cancer Treatment

2/11/2015 11:05 am

(Allegheny Health Network) Feb 10, 2015 - Aggressive surgery to remove all visible disease in ovarian cancer patients may have little benefit for some patients whose cancer is highly advanced at diagnosis, according to a study published in today’s Journal of Clinical Oncology.

A Never-Ending Genetic Quest

2/10/2015 11:05 am

(New York Times) Feb 9, 2015 - Mary-Claire King discovered BRCA1, the so-called breast cancer gene, and now believes every woman should be tested. A condensed and edited version of an interview with Dr. King follows.

ASCO: 'High-Risk' Project 'Must Be Done'

1/22/2015 11:03 am

(Medscape Medical News) Jan 22, 2015 - The organization has been claiming that CancerLinQ will revolutionize cancer care for months. Now they have a technology partner to help them.

Celgene, Biotech's Ace Dealmaker, Bets on Canada's Zymeworks

1/22/2015 11:03 am

(Forbes) Jan 21, 2015 - Celgene, the big maker of blood cancer drugs, has gained a reputation for anointing biotech startups before they break out. Now it’s betting on a little Canadian biotech, Zymeworks, with technology for engineering new types of targeted antibody drugs.

OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

1/16/2015 06:28 am

(Yahoo! Finance) Jan 16, 2015 - OncoGenex Pharmaceuticals, Inc. today announced that the AFFINITY trial is continuing as planned based upon completion of the interim futility analysis and the recommendation of the Independent Data Monitoring Committee (IDMC).

OncoGenex Regains Rights to Prostate and Lung Cancer Drug

1/5/2015 11:51 am

(Drug Discovery & Development) Dec 30, 2014 - OncoGenex Pharmaceuticals Inc. announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.

OncoGenex Announces Results from the Phase 2 Borealis-1(TM) Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer

12/19/2014 11:52 am

(istockanalyst.com) Dec 19, 2014 - OncoGenex Pharmaceuticals, Inc. today announced results from the randomized, controlled Phase 2 Borealis-1™ trial evaluating low and high dose (600mg and 1000mg) apatorsen in combination with gemcitabine/cisplatin chemotherapy compared to chemotherapy alone in the treatment of metastatic bladder cancer.

OncoGenex Announces Completion of Patient Enrollment in the Rainier(TM) Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE(R) plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

12/16/2014 12:08 pm

(OncoGenex) Dec 16, 2014 - OncoGenex Pharmaceuticals, Inc. announced today that patient enrollment has been completed in the Rainier™ clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine in patients with previously untreated metastatic pancreatic cancer.

Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement

12/3/2014 11:05 am

(TheStreet) Dec 2, 2014 - Puma Biotechnology is pushing back an approval filing for its breast cancer drug neratinib into 2016 -- almost a one year delay.

Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib

11/17/2014 05:01 am

(Yahoo! Finance) Nov 16, 2014 - Exelixis, Inc. today announced preliminary results from a phase 1 investigator-sponsored trial (IST) evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma.

Researchers Find New Target for Kidney Cancer Therapy

11/11/2014 06:00 am

(UC Academic Health Center) Nov 10, 2014 - Cincinnati Cancer Center (CCC) researchers have discovered that a membrane channel, Transient Receptor Potential Melastatin 3, or TRPM3, promotes growth of kidney cancer tumors, and targeting this channel therapeutically could lead to more treatments for a disease, which currently has few treatment options.

FDA Approves Ramucirumab For Advanced Gastric or GE Junction Adenocarcinoma

11/6/2014 06:01 am

(ASCO in Action) Nov 5, 2014 - On November 5, 2014, the U. S. Food and Drug Administration approved ramucirumab (Cyramza®, Eli Lilly and Company) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Amgen Ovarian Cancer Drug Fails to Improve Overall Survival

11/4/2014 06:01 am

(Reuters) Nov 4, 2014 - Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial.

Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer

11/4/2014 02:05 am

(Amgen) Nov 4, 2014 - Amgen today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not demonstrate a statistically significant improvement in overall survival.

OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer

9/16/2014 12:02 pm

(TheStreet) Sept 16, 2014 - OncoGenex Pharmaceuticals, Inc. announced today that patient enrollment has been completed in the Phase 3 AFFINITY trial.

Hacker Breached HealthCare.gov Insurance Site

9/5/2014 06:03 am

(Wall Street Journal) Sept 4, 2014 - A hacker broke into part of the HealthCare.gov insurance enrollment website in July and uploaded malicious software, according to federal officials.

Gilead Close to Sending $84,000 Drug to Poor Countries

9/5/2014 06:03 am

(Bloomberg) Sept 4, 2014 - Gilead Sciences Inc. is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.